Immunogen, Inc.

-0.29 (-3.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.45B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16.03 Million
Adjusted EPS-$0.19
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

ImmunoGen, Inc. Stock, NASDAQ:IMGN

830 Winter Street, Waltham, Massachusetts 02451-1477
United States of America
Phone: +1.781.895.0600
Number of Employees: 75


ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.